I wonder if they tried it with the OTC version of lactoferrin and it didn't work, or did they purposely use the research type because it costs more, is regulated, and on UFs investment portfolio? I don't take "expert's" pronouncements at face value anymore; what a shame.
I wonder if they tried it with the OTC version of lactoferrin and it didn’t work, or did they purposely use the research type because it costs more, is regulated, and on UFs investment portfolio?
~~~~~~~~~~~~~~~~~~~~~~~~
Here is the original link where the medical paper is accessed….
https://www.mdpi.com/2076-0817/10/11/1514/htm
Pathogens is an international, peer-reviewed, open access journal of pathogens and pathogen-host interactions published monthly online by MDPI..... this is the “Multidisciplinary Digital Publishing Institute” and they are based in Switzerland. On Nov. 20, 2021, they put out this piece called “Highly Specific Sigma Receptor Ligands Exhibit Anti-Viral Properties in SARS-CoV-2 Infected Cells.”
Here is a copy and paste of I think is the heart of what this medical paper is saying in section 2.3 ... I don’t have time to review it again right now but I suspect that this sort of addresses the question you asked….
In our investigations into sigma-binding ligands, including diphenhydramine, we sought to reduce the EC50 by addition of another safe, and well characterized protein from milk, lactoferrin. The host-iron sequestration protein lactoferrin was reported to exhibit direct antiviral activity against SARS-CoV-2 [28,29], is broadly antimicrobial, and possesses host immunostimulatory properties. We tested combinations of lactoferrin with diphenhydramine to measure effects on reduction of EC50. Co-administration of 400 μg/mL of lactoferrin with diphenhydramine further reduced SARS-CoV-2 induced cytotoxicity and decreased the EC50 by 55.5% to 54.2 μg/mL (185.7 μM; Figure 8C,D). The antiviral enhancement effects of lactoferrin are more apparent at lower, therapeutically relevant concentrations of diphenhydramine (Figure 8E). Inhibition of viral replication was also investigated by qPCR (Figure 8F). Lactoferrin (400 μg/mL) was able to decrease N-protein RNA copies by 28.0% 48 h after infection, compared to DMSO alone controls while 40 μg/mL diphenhydramine alone resulted in 32.2% reduction. When combined, they inhibited 99.97% of N-protein RNA copies, a 3-log reduction that was highly significant. These data demonstrate that combinations of two over-the-counter compounds, with well characterized safety profiles, have synergistic effects on inhibition of SARS-CoV-2.